Mirum Pharmaceuticals (MIRM) Revenue & Revenue Breakdown
Mirum Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$186.37M
Latest Revenue (Q)
$69.22M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
Mirum Pharmaceuticals Revenue by Period
Mirum Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $186.37M | 141.85% |
| 2022-12-31 | $77.06M | 302.66% |
| 2021-12-31 | $19.14M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | - |
Mirum Pharmaceuticals generated $186.37M in revenue during NA 2023, up 141.85% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Mirum Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $69.22M | -0.48% |
| 2023-12-31 | $69.55M | 45.74% |
| 2023-09-30 | $47.73M | 27.28% |
| 2023-06-30 | $37.50M | 18.67% |
| 2023-03-31 | $31.60M | 13.23% |
| 2022-12-31 | $27.91M | 48.59% |
| 2022-09-30 | $18.78M | 7.41% |
| 2022-06-30 | $17.48M | 35.62% |
| 2022-03-31 | $12.89M | 310.83% |
| 2021-12-31 | $3.14M | -37.24% |
| 2021-09-30 | $5.00M | -54.55% |
| 2021-06-30 | $11.00M | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | - |
Mirum Pharmaceuticals generated $69.22M in revenue during Q1 2024, up -0.48% compared to the previous quarter, and up 248.05% compared to the same period a year ago.
Mirum Pharmaceuticals Revenue Breakdown
Mirum Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Product | $178.87M | $75.06M | $3.14M |
| License Revenue | $7.50M | - | - |
| License | - | $2.00M | $16.00M |
Mirum Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (95.98%), and License Revenue (4.02%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 |
|---|---|---|---|---|---|---|---|---|---|
| License and Other Revenue | $305.00K | - | - | - | - | - | - | - | - |
| Product | $68.92M | $69.55M | $47.73M | $32.50M | $29.10M | $27.91M | $18.78M | $17.48M | $10.89M |
| License Revenue | - | - | $7.50M | - | - | - | - | - | - |
| License | - | - | - | $5.00M | $2.50M | - | - | - | $2.00M |
Mirum Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (99.56%), and License and Other Revenue (0.44%).
Mirum Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 |
|---|---|
| UNITED STATES | $146.70M |
| Rest of World | $32.17M |
Mirum Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (82.01%), and Rest of World (17.99%).
Quarterly Revenue by Country
| Country | Mar 24 |
|---|---|
| Rest Of World | $12.81M |
| UNITED STATES | $56.11M |
Mirum Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (81.42%), and Rest Of World (18.58%).
Mirum Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| IMCR | Immunocore | $249.43M | $75.40M |
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| MIRM | Mirum Pharmaceuticals | $186.37M | $69.22M |
| ARQT | Arcutis Biotherapeutics | $59.61M | $30.86M |
| VECT | VectivBio | $27.34M | $676.00K |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| CERE | Cerevel Therapeutics | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| LRMR | Larimar Therapeutics | - | - |
| KALV | KalVista Pharmaceuticals | - | - |
| MLTX | MoonLake Immunotherapeutics | - | - |
MIRM Revenue FAQ
What is Mirum Pharmaceuticals’s yearly revenue?
Mirum Pharmaceuticals's yearly revenue for 2023 was $186.37M, representing an increase of 141.85% compared to 2022. The company's yearly revenue for 2022 was $77.06M, representing an increase of 302.66% compared to 2021. MIRM's yearly revenue for 2021 was $19.14M, representing an increase of 100.00% compared to 2020.
What is Mirum Pharmaceuticals’s quarterly revenue?
Mirum Pharmaceuticals's quarterly revenue for Q1 2024 was $69.22M, a -0.48% decrease from the previous quarter (Q4 2023), and a 119.07% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $69.55M, a 45.74% increase from the previous quarter (Q3 2023), and a 149.24% increase year-over-year (Q4 2022). MIRM's quarterly revenue for Q3 2023 was $47.72M, a 27.28% increase from the previous quarter (Q2 2023), and a 154.13% increase year-over-year (Q3 2022).
What is Mirum Pharmaceuticals’s revenue growth rate?
Mirum Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 873.84%, and for the last 5 years (2019-2023) was 0%.
What are Mirum Pharmaceuticals’s revenue streams?
Mirum Pharmaceuticals's revenue streams in c 23 are Product, and License Revenue. Product generated $178.87M in revenue, accounting 95.98% of the company's total revenue, up 138.30% year-over-year. License Revenue generated $7.5M in revenue, accounting 4.02% of the company's total revenue
What is Mirum Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Mirum Pharmaceuticals was Product. This segment made a revenue of $178.87M, representing 95.98% of the company's total revenue.